Skip to main content
Log in

Plasma Protein Binding of Etomidate in Patients with Renal Failure or Hepatic Cirrhosis

  • Original Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

The influence of renal failure and of hepatic cirrhosis on the plasma protein binding of etomidate, an intravenous anaesthetic agent of basic nature, has been investigated. The percentage of free etomidate in plasma containing 1 μg/ml was markedly increased in patients with renal failure and in patients with hepatic cirrhosis, when compared with a group of healthy volunteers (43.4 ± 2.9% and 44.2 ± 2.1 versus 24.9 ± 1.4%). This decrease in binding correlated inversely with serum albumin levels in both conditions (r = −0.88 and r = −0.72, respectively) but a slight decrease in the amount bound per mole of albumin was also apparent in both types of disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Preliminary results presented at the 7th International Congress of Pharmacology, Paris, July 1978.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carlos, R., Calvo, R. & Erill, S. Plasma Protein Binding of Etomidate in Patients with Renal Failure or Hepatic Cirrhosis. Clin-Pharmacokinet 4, 144–148 (1979). https://doi.org/10.2165/00003088-197904020-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-197904020-00007

Keywords

Navigation